Leveraged buyouts, growth capital, angel investments, and seed funding—these private transactions take place, largely out of the public’s eye, not only in Connecticut or Silicon Valley, but also in Beijing, Shenzhen, and Shanghai.
In 2016, China’s private equity (PE) and venture capital (VC) firms raised over $70 billion, more than 20% of total such funding globally. At the same time, these firms also deployed capital to the tune of $223 billion, accounting for more than 70% of global PE/VC investments.
As late comers, these Chinese firms have rapidly grown into formidable financiers. Most Chinese PE firms are particularly interested in products and services that can be commercialized and scaled up quickly in China. They tend to invest in areas that align with China’s shift to a more consumer-driven economy. Meanwhile, Chinese VCs have been active players globally, particularly in Silicon Valley. They have focused on areas such as artificial intelligence, Internet of Things, and electric vehicles.
Sailing Capital is a private equity firm with a total of ¥50 billion ($8 billion) assets under management. It specializes in cross-border investments and offers professional services to Chinese companies that want to invest abroad. The firm’s overseas investments focus on the healthcare and consumer spaces. Its investors include domestic Chinese enterprise groups, listed companies, and other financial institutions.
Fan Fu
Shanghai: (021) 3612.6800
CRM@sailing-capital.com
In March 2016, Sailing Capital, along with Gloria Pharma, co-led a $14 million seed investment in Proteus Digital Health, a Silicon Valley-based remote patient monitoring company. In November 2015, Sailing Capital, along with H&S Ventures LLC, Longitude Capital, and Chow Tai Fook Enterprises, co-led a Series B investment in ALPHAEON, an Irvine, CA-based healthcare services provider.
In October 2015, Sailing Capital, along with Clough Capital Partners, Morgenthaler Ventures, Kleiner Perkins Caufield & Byers, Technology Partners, and GSM Fund LLC, co-led a Series E $40 million investment in Elcelyx, a San Diego-based healthcare startup specializing in Gut Sensory Modulation technology.